Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lytix Biopharma AS's Total Assets for the quarter that ended in Mar. 2026 was kr128.80 Mil.
During the past 12 months, Lytix Biopharma AS's average Total Assets Growth Rate was -29.20% per year.
During the past 3 years, the average Total Assets Growth Rate was 1.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 26.00% per year.
During the past 8 years, Lytix Biopharma AS's highest 3-Year average Total Assets Growth Rate was 52.90%. The lowest was -15.10%. And the median was 26.90%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Lytix Biopharma AS's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Lytix Biopharma AS Total Assets Related Terms
Lytix Biopharma AS Total Assets Historical Data
* Premium members only.
The historical data trend for Lytix Biopharma AS's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Lytix Biopharma AS's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lytix Biopharma AS (OSL:LYTIX) has a Total Assets of kr128.80 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Lytix Biopharma AS and its competitors.
Is Lytix Biopharma AS's Total Assets too high?
Lytix Biopharma AS's current Total Assets is kr128.80 Mil. Overall, Lytix Biopharma AS has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's Total Assets compare to VRTX and REGN?
Lytix Biopharma AS's Total Assets of kr128.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Lytix Biopharma AS and its competitors. Lytix Biopharma AS's current Total Assets is kr128.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Based on GuruFocus' analysis, Lytix Biopharma AS (OSL:LYTIX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.17, compared to a current price of kr8.74 — trading 5041.2% above its estimated fair value. The current Total Assets is kr128.80 Mil. Lytix Biopharma AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Lytix Biopharma AS (OSL:LYTIX), the current Total Assets is kr128.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lytix Biopharma AS (OSL:LYTIX) Overvalued in 2026?
Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued.
The current stock price of kr8.74 is trading 5041.2% above its estimated GF Value™ of kr0.17.
GuruFocus considers Lytix Biopharma AS to be Significantly Overvalued.
Key valuation signals for OSL:LYTIX:
Total Assets: kr128.80 Mil
GF Value™: kr0.17 vs. price of kr8.74 (5041.2% above fair value)
No single metric tells the full story. See the OSL:LYTIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
28GF Score
Get the complete analysis for OSL:LYTIX
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:LYTIX has been successfully added to your 
